Ironwood price target raised to $18 from $15 at Capital One

Capital One raised the firm’s price target on Ironwood to $18 from $15 and keeps an Overweight rating on the shares, noting the stock has outperformed year-to-date, as it is up ~30%. The analyst believes the most important near-term catalyst for Ironwood is the upcoming top line data readout on apraglutide, a synthetic GLP-2 analog in Phase 3 for Short Bowel Syndrome with Intestinal Failure that has fast track designation, which could expedite regulatory approval.